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This application relates to the functional identi?cation and 
characterization of a nucleic acid molecule encoding a triter 
pene synthase, in particular botryococcene synthase. Also 
described are host cells comprising the nucleic acid mol 
ecules of this invention, proteins encoded by the nucleic acid 
molecules and methods for using the nucleic acid molecules, 
transformed hosts and encoded proteins to produce high lev 
els of triterpene hydrocarbons. 
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B OT R YOC C 0C US BRA UNII TRITERPENE 
SYNTHASE PROTEINS AND NUCLEIC ACID 
MOLECULES, AND METHODS FOR THEIR 
USE 
CLAIM TO PRIORITY 
This application is a divisional of US. application Ser. No. 
12/539,442, ?led Aug. 11, 2009, now US. Pat. No. 7,985, 
568, Which claims priority under 35 U.S.C. 119(e) to US. 
provisional application No. 61/087,920 ?led Aug. 11, 2008, 
incorporated in its entirety by reference. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing Which 
has been submitted via EFS-Web and is hereby incorporated 
by reference in its entirety. Said ASCII copy, created on Oct. 
12, 2009, is named 14726673.txt, and is 14,577 bytes in siZe. 
FIELD OF THE INVENTION 
This invention relates to a triterpene synthase, in particular 
a botryococcene synthase, proteins and nucleic acid mol 
ecules and their use. 
BACKGROUND OF THE INVENTION 
Squalene and botryococcene are related by their putative 
biosynthetic origins from the condensation of tWo famesyl 
diphosphate (FPP) molecules, and are knoWn to be synthe 
siZed byrace B, a fresh Water green algae (Okada. et al., 
(1995). Journal OfApplied Phycology 555-559; MetZger and 
Largeau (2005). Applied Microbiology and Biotechnology 
486-496.) Botryococcene is further modi?ed in and becomes 
methylated With 1, 2, 3 or 4 additional methyl substituents 
catalyZed by a special triterpene methyl transferase. Botryo 
cocene and its methylated derivatives have attracted signi? 
cant attention because these molecules are thought to be the 
progenitors to current oil shale deposits (Summons et al., 
(2002) Organic Geochemistry 99-109; Walters et al., (2005) 
Aapg Bulletin 1239-1 244.) and because they are considered 
promising reneWable, alternative biofuels (Banerjee et al., 
(2002). Critical Reviews in Biotechnology 245-279.) For 
example, Hillen et al. (1982) Biotechnology And Bioengi 
neering 193-205) previously reported on the catalytic crack 
ing of methylated botryococcenes and squalene derivatives, 
and observed an overall conversion of 97% of the oil to 
combustible fuels under standard cracking conditions. Over 
all, 67% of the oil Was converted to gasoline grade fuel, 15% 
to aviation turbine fuel, and 15% to diesel fuel With a residual 
of only 3%. Hence, catalytic hydrolysis (as performed in 
standard petroleum re?neries) of these highly branched, 
poly-unsaturated triterpenes results in the generation of 
hydrocarbon fractions that are chemically equivalent to those 
derived from current petroleum deposits and are of direct 
utility as fuels for internal combustion engines, as Well as 
feedstocks for chemical manufacturing (Banerjee et al., 
(2002)). 
Up to this time, these energy-rich triterpene oils have only 
been available from cultures of a rather sloW groWing green 
algae that does not lend itself to large-scale or fermentation 
type culturing conditions (Casadevall et al., (1985). Biotech 
nology and Bioengineering 286-295). 
BRIEF DESCRIPTION OF THE INVENTION 
The current disclosure describes the functional identi?ca 
tion and characterization of the gene coding for a triterpene 
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2 
synthase in particular a botryococcene synthase, BBS, 
enZyme. The identi?cation of the botryococcene synthase 
gene noW provides an alternative means of generating impor 
tant raW materials for the reliable and cost effective produc 
tion of an energy-rich, reneWable, and sustainable biofuel 
source (FIG. 3). For example, the co-expression of the bot 
ryococcene synthase gene in combination With a suitable FPP 
synthase and triterpene methyltransferase genes in transgenic 
terrestrial or aquatic plants could yield a production platform 
for the methylated triterpenes. These compounds could be 
derived from the metabolic diversion of CO2 ?xed in the 
process of photosynthesis ?oWing directly into triterpene bio 
synthesis and accumulation. The feasibility of this engineer 
ing strategy for the production of large amounts of high 
valued sesquiterpenes, terpenes consisting of 15 carbons 
rather than the 30 carbons found in triterpenes, Was recently 
demonstrated. (Wu et al., (2006) Nature Biotechnology 
1441 1447). 
The botryococcene synthase of this invention is a triterpene 
synthase enZyme catalyZing the reductive condensation of 2 
famesyl diphosphate (FPP) substrate molecules yielding bot 
ryococcene, a 30-carbon, branched-chain hydrocarbon. 
More speci?cally, disclosed herein is the DNA and protein 
sequence of, and the functional characterization for, the race 
B botryococcene synthase gene Which, When expressed in a 
heterologous host such as bacteria, yeast or plants yields a 
protein that, When mixed With a lysate and reducing equiva 
lents in the form of NADPH, provides an enZyme activity that 
catalyZes a unique chemical condensation of 2 FPP mol 
ecules, creating a branched, triterpene hydrocarbon knoWn as 
botryococcene. A schematic diagram of the reaction cata 
lyZed by the botryococcene synthase enZyme is shoWn in 
FIG. 1. Like squalene synthase (Blagg et al., (2002) J. Am. 
Chem. Soc. 8846-8853), botryococcene synthase is predicted 
to catalyZe a 2 step reaction. The ?rst step condenses the 2 
FPP substrate molecules into a pre-squalene diphosphate 
intermediate (PSPP). When NADPH is provided, squalene 
synthase reduces the PSPP to a linkage of carbons 1 and 1' of 
the respective FPP molecules. In contrast, When botryococ 
cene synthase is provided NADPH, the PSPP undergoes a 
different reducing rearrangement to botryococcene With a 
linkage of carbon 3 of one FPP starter molecule to carbon 1' 
of the second FPP starter molecule. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts the biosynthetic pathWays for botryococ 
cene and squalene. Both triterpenes are derived from an initial 
condensation of 2 FPP molecules to form presqualene 
diphosphate (PSPP), Which is subsequently cleaved and 
reduced to form either botryococcene or squalene. 
FIG. 2 depicts an overvieW of the hydrocracking process of 
a typical, C34 botryococcene to yield fuel suitable for com 
bustion engines. Brie?y, botryococcocenes are treated With 
high pressure H2 at high temperatures With a Pd catalyst to 
give a variety of organic molecules, Which can be further 
distilled into various classes of fuel. 
FIG. 3 depicts a strategy for engineering an alternative 
biofuels production platform into terrestrial or aquatic plants. 
Genes coding for the biochemical steps for synthesis of bot 
ryococcocenes Would be introduced into plants such that the 
respective catalytic steps (FPP synthase, triterpene synthase 
and triterpene methyltransferase activities) Would be targeted 
to the chloroplast compartment. The introduced enZyme 
activities Would hence divert photosynthetically ?xed CO2 
directly into methylated triterpene biosynthesis. 
US 8,592,180 B2 
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FIG. 4 presents the DNA sequence for the botryococcene 
synthase cDNA, SEQ ID NO: 1. The start and stop codons are 
shown in bold. 
FIG. 5 presents the amino acid sequence for the botryococ 
cene synthase protein, SEQ ID NO: 2, predicted from the 
corresponding cDNA sequence shoWn in FIG. 4. 
FIG. 6 depicts an alignment comparison of selection 
regions/domains of various squalene synthase proteins from 
Bolryococcus (BSS), tobacco (N. Zabacum), Arabidopsis (A. 
Zhaliana), corn (Z. mays), rat (R. rallus) and yeast (S. cerevi 
siae) to that for the botryococcene synthase (BBS). Domains 
I-VI Were identi?ed as highly conserved amongst diverse 
squalene synthases, and domains III-V Were previously cor 
related With the particular steps in catalysis as noted. 
Sequences displayed across the 5 domains are: BBS, SEQ ID 
NO: 3, 4, 5, 6, and 7; BSS, SEQ ID NO: 8, 9, 10, 11, and 12; 
N. Zabacum SEQ ID NO: 13, 14, 15, 16, and 17; A. Zhaliana, 
SEQ ID NO: 18, 19, 20, 21, and 22; Z. mays, SEQ ID NO: 23, 
24, 25, 26 and 27; R. razzus, SEQ ID NO: 28, 29, 30, 31, ans 
32; and S. cerevisiae SEQ ID NO: 33, 34, 35, 36 and 37. 
FIG. 7 depicts the puri?cation of hexa-histidine tagged 
(SEQ ID NO: 44) BBS enzyme. E. coli cells over-expressing 
the botryococcene synthase gene harboring an amino termi 
nal hexa-histidine puri?cation tag (SEQ ID NO: 44) Were 
used to prepare an initial cell lysate (crude lysate), Which Was 
then subject to nickle af?nity chromatography. The crude 
lysate Was applied to the a?inity column, folloWed by Wash 
ing With buffer containing increasing concentrations of imi 
dazole (?oW (buffer Without imidazole, to buffer containing 
250 mM imidazole) and the respective column fractions col 
lected for SDS-PAGE analysis.Aliquots of each fraction Were 
resolved by SDS-PAGE and the gel stained With Coomassie 
Blue, a general protein stain. Molecular Weight standards are 
noted as marker and the expected size for the his-tagged BBS 
protein is noted by the arroW. 
FIG. 8 illustrates the botryococcene synthase enzyme 
assay. 
FIG. 9 depicts the enzyme activity of puri?ed BBS protein, 
activity associated With a B. braunii lysate (boty lys), and 
BBS combined With lysate (BBS+boty lys) With or Without 
NADPH. BBS containing an N-terminal hexa-histidine tag 
(SEQ ID NO: 44) Was expressed in E. coli and puri?ed from 
bacterial lysate by nickel af?nity chromatography according 
to the manufacturer (Novagen) (see FIG. 7). 
FIG. 10 depicts GC chromatographs of hexane extracts 
prepared from TN7 yeast (a) and TN7 yeast expressing BBS 
(b). The mass spectrum for the unique peak found in the 
TN7-BBS culture With a retention time of 16.20 is shoWn in 
panel c. The mass spectrum matches that of presqualene 
alcohol (PSOH) as described by Edmond et al. (1971) .1. Biol. 
Chem. 6254-6251. 
FIG. 11 depicts GC chromatographs of hexane extracts 
prepared from TN7 yeast (a) and TN7 yeast expressing a full 
length B. braunii squalene synthase gene (b). Identi?cation of 
the novel compound accumulating in TN7 yeast expressing 
the squalene synthase gene (corresponding to the peak With 
retention time of approximately 14) Was based on mass spec 
tral comparisons (not shoWn) and identical chromatographic 
behavior of an authentic squalene (25 ng) standard (c). 
FIG. 12 depicts the accumulation of squalene in TN7 yeast 
over-expressing a Bolryococcus braunii squalene synthase 
gene. 
DETAILED DESCRIPTION OF THE INVENTION 
The current disclosure describes the functional identi?ca 
tion and characterization of the gene coding for a botryococ 
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4 
cene synthase, BBS, enzyme, nucleic acid molecules e.g, 
SEQ ID NO: 1, encoding a botryococcene synthase, BBS, 
polypeptide of this invention, e.g., SEQ ID NO: 2 and meth 
ods for their use. 
The polypeptides of this invention include for example 
polypeptides comprising the amino acid sequence set forth in 
SEQ ID NO:2 and fragments thereof. Preferably the polypep 
tide fragments have triterpene synthase activity. The polypep 
tides of this invention may comprise one or more peptide 
domains I, II, III, IV, V and IV, Wherein domain I comprises 
LPQELQDPICIFYL (SEQ ID NO: 3), domain II comprises 
LRALDTVEDDMN LKSETK (SEQ ID NO: 4), domain III 
comprises YCHYVAGSCGIAVTKVIV (SEQ ID NO: 5), 
domain IV comprises GLLLQKANIITDYNED (SEQ ID 
NO: 6), and domain V comprises ALALLLVTAFGHLS 
(SEQ ID NO: 7). 
The polypeptides of this invention may also contain one or 
more modi?ed amino acids. The presence of modi?ed amino 
acids may be advantageous in, for example, increasing triter 
pene synthase catalytic activity or increasing polypeptide 
stability. Amino acid(s) are modi?ed, for example, co-trans 
lationally or post-translationally during recombinant produc 
tion (e. g., N-linked glycosylation at NiXiS/T motifs dur 
ing expression in mammalian cells) or modi?ed by synthetic 
means.Accordingly, a “mutant”, “variant” or “modi?ed” pro 
tein, enzyme, polynucleotide, gene, or cell, means a protein, 
enzyme, polynucleotide, gene, or cell, that has been altered or 
derived, or is in some Way different or changed, from a parent 
protein, enzyme, polynucleotide, gene, or cell. A mutant or 
modi?ed protein or enzyme is usually, although not necessar 
ily, expressed from a mutant polynucleotide or gene. 
A “paren ” protein, enzyme, polynucleotide, gene, or cell, 
is any protein, enzyme, polynucleotide, gene, or cell, from 
Which any other protein, enzyme, polynucleotide, gene, or 
cell, is derived or made, using any methods, tools or tech 
niques, and Whether or not the parent is itself native or mutant. 
A parent polynucleotide or gene encodes for a parent protein 
or enzyme. 
A “mutation” means any process or mechanism resulting 
in a mutant protein, enzyme, polynucleotide, gene, or cell. 
This includes any mutation in Which a protein, enzyme, poly 
nucleotide, or gene sequence is altered, and any detectable 
change in a cell arising from such a mutation. Typically, a 
mutation occurs in a polynucleotide or gene sequence, by 
point mutations, deletions, or insertions of single or multiple 
nucleotide residues. A mutation includes polynucleotide 
alterations arising Within a protein-encoding region of a gene 
as Well as alterations in regions outside of a protein-encoding 
sequence, such as, but not limited to, regulatory or promoter 
sequences. A mutation in a gene can be “silent”, i.e., not 
re?ected in an amino acid alteration upon expression, leading 
to a “sequence-conservative” variant of the gene. This gener 
ally arises because of degeneracy of the genetic code Wherein 
more than one codon codes for the same amino acid. 
Non-limiting examples of a modi?ed amino acid include a 
glycosylated amino acid, a sulfated amino acid, a prenlyated 
(e.g., farnesylated, geranylgeranylated) amino acid, an acety 
lated amino acid, an acylated amino acid, a pegylated amino 
acid, a biotinylated amino acid, a carboxylated amino acid, a 
phosphorylated amino acid, and the like. References 
adequate to guide one of skill in the modi?cation of amino 
acids are replete throughout the literature. Example protocols 
are found in Walker (1998) Protein Protocols on CD-ROM 
(Humana Press, ToWata, N.J.). 
Recombinant methods for producing and isolating the trit 
erpene synthase polypeptides and modi?ed triterpene syn 
thase polypeptides of the invention are described herein. In 
US 8,592,180 B2 
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addition to recombinant production, the polypeptides may be 
produced by direct peptide synthesis using solid-phase tech 
niques (e.g., Stewart et al. (1969) Solid-Phase Peptide Syn 
thesis (WH Freeman Co, San Francisco); and Merri?eld 
(1963) .1. Am. Chem. Soc. 85: 2149-2154; each of Which is 
incorporated by reference). Peptide synthesis may be per 
formed using manual techniques or by automation. Auto 
mated synthesis may be achieved, for example, using Applied 
Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster 
City, Calif.) in accordance With the instructions provided by 
the manufacturer. 
A “protein” or “polypeptide”, Which terms are used inter 
changeably herein, comprises one or more chains of chemical 
building blocks called amino acids that are linked together by 
chemical bonds called peptide bonds. An “enzyme” means 
any substance, composed Wholly or largely of protein, that 
catalyzes or promotes, more or less speci?cally, one or more 
chemical or biochemical reactions. A “native” or “Wild-type” 
protein, enzyme, polynucleotide, gene, or cell, means a pro 
tein, enzyme, polynucleotide, gene, or cell that occurs in 
nature (Who se form predominates in natural populations). 
Accordingly, in various embodiments, isolated or recom 
binant polypeptides comprising the amino acid sequence set 
forth in SEQ ID NO:2 are provided. The polypeptides include 
up to 35, 25, 10, 5, 4, 3, 2 or 1 conservative amino acid 
substitutions. 
“Conservative amino acid substitutions” or, simply, “con 
servative variations” of a particular sequence refers to the 
replacement of one amino acid, or series of amino acids, With 
essentially identical amino acid or series of amino acids. One 
of skill Will recognize that individual substitutions, deletions 
or additions Which alter, add or delete a single amino acid or 
a percentage of amino acids in an encoded sequence result in 
“conservative variations” Where the alterations result in the 
deletion of an amino acid, addition of an amino acid, or 
substitution of an amino acid With a functionally similar 
amino acid. 
Conservative substitution tables providing functionally 
similar amino acids are Well knoWn in the art. For example, 
one conservative substitution group includes Alanine (A), 
Serine (S), and Threonine (T). Another conservative substi 
tution group includes Aspartic acid (D) and Glutamic acid 
(E). Another conservative substitution group includes Aspar 
agine (N) and Glutamine (Q). Yet another conservative sub 
stitution group includes Arginine (R) and Lysine (K). Another 
conservative substitution group includes lsoleucine, (1) Leu 
cine (L), Methionine (M), and Valine (V). Another conserva 
tive substitution group includes Phenylalanine (F), Tyrosine 
(Y), and Tryptophan (W). 
Thus, “conservative amino acid substitutions” of a listed 
polypeptide sequence (e.g., SEQ ID NO:2) include substitu 
tions of a percentage, typically less than 10%, of the amino 
acids of the polypeptide sequence, With an amino acid of the 
same conservative substitution group. Accordingly, a conser 
vatively substituted variation of a polypeptide of the invention 
can contain, for example, substitutions of 35, 25, 10, 5, 4, 3, 
2 or 1 amino acid With an amino acid of the same conservative 
substitution group. 
It is understood that the addition of sequences that do not 
alter the encoded activity of a nucleic acid molecule, such as 
the addition of a non-functional or non-coding sequence, is a 
conservative variation of the basic nucleic acid molecule. The 
“activity” of an enzyme is a measure of its ability to catalyze 
a reaction, i.e., to “function”, and may be expressed as the rate 
at Which the product of the reaction is produced. For example, 
enzyme activity can be represented as the amount of product 
produced per unit of time or per unit of enzyme (e.g., con 
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centration or Weight), or in terms of a?inity or dissociation 
constants. As used interchangeably herein a “triterpene syn 
thase activity”, “biological activity of triterpene synthase” or 
“functional activity of triterpene synthase”, refers to an activ 
ity exerted by a triterpene synthase protein, polypeptide or 
nucleic acid molecule on a triterpene synthase polypeptide 
substrate, as determined in vivo, or in vitro, according to 
standard techniques. 
One of skill in the art Will appreciate that many conserva 
tive substitutions of the nucleic acid constructs Which are 
disclosed herein yield a functionally identical construct. For 
example, oWing to the degeneracy of the genetic code, “silent 
substitutions” (i.e., substitutions in a nucleic acid sequence 
Which do not result in an alteration in an encoded polypep 
tide) are an implied feature of every nucleic acid sequence 
Which encodes an amino acid. 
Similarly, “conservative amino acid substitutions,” in 
Which one or a feW amino acids in an amino acid sequence are 
substituted With different amino acids With highly similar 
properties, are also readily identi?ed as being highly similar 
to a disclosed construct. Families of amino acid residues 
having similar side chains have been de?ned in the art. These 
families include amino acids With basic side chains (e.g., 
lysine, arginine, histidine), acidic side chains (e.g., aspartic 
acid, glutamic acid), uncharged polar side chains (e.g., gly 
cine, asparagine, glutamine, serine, threonine, tyrosine, cys 
teine), nonpolar side chains (e.g., alanine, valine, leucine, 
isoleucine, proline, phenylalanine, methionine, tryptophan), 
beta-branched side chains (e.g., threonine, valine, isoleucine) 
and aromatic side chains (e. g., tyrosine, phenylalanine, tryp 
tophan, histidine). Such conservative variations of each dis 
closed sequence are a feature of the polypeptides provided 
herein. 
It Will be appreciated by those skilled in the art that due to 
the degeneracy of the genetic code, a multitude of nucleotide 
sequences encoding modi?ed triterpene synthase polypep 
tides of the invention may be produced, some of Which bear 
substantial identity to the nucleic acid sequences explicitly 
disclosed herein. For instance, codons AGA, AGG, CGA, 
CGC, CGG, and CGU all encode the amino acid arginine. 
Thus, at every position in the nucleic acid molecules of the 
invention Where an arginine is speci?ed by a codon, the codon 
can be altered to any of the corresponding codons described 
above Without altering the encoded polypeptide. It is under 
stood that U in an RNA sequence corresponds to T in a DNA 
sequence. 
“Conservative variants” are proteins or enzymes in Which a 
given amino acid residue has been changed Without altering 
overall conformation and function of the protein or enzyme, 
including, but not limited to, replacement of an amino acid 
With one having similar properties, including polar or non 
polar character, size, shape and charge. Amino acids other 
than those indicated as conserved may differ in a protein or 
enzyme so that the percent protein or amino acid sequence 
similarity betWeen any tWo proteins of similar function may 
vary and can be, for example, at least 30%, at least 50%, at 
least 70%, at least 80%, at least 90%, at least 95%, at least 
98% or at least 99%, as determined according to an alignment 
scheme. As referred to herein, “sequence similarity” means 
the extent to Which nucleotide or protein sequences are 
related. The extent of similarity betWeen tWo sequences can 
be based on percent sequence identity and/or conservation. 
“Sequence identity” herein means the extent to Which tWo 
nucleotide or amino acid sequences are invariant. “Sequence 
alignment” means the process of lining up tWo or more 
sequences to achieve maximal levels of identity (and, in the 
case of amino acid sequences, conservation) for the purpose 
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of assessing the degree of similarity. Numerous methods for 
aligning sequences and assessing similarity/identity are 
known in the art such as, for example, the Cluster Method, 
Wherein similarity is based on the MEGALIGN algorithm, as 
Well as BLASTN, BLASTP, and FASTA (Lipman and Pear 
son, (1985) Science 22; 227(4693):1435-41; Pearson and 
Lipman, (1988) Proc Natl Acad Sci USA; 85(8):2444-8). 
When using all of these programs, the preferred settings are 
those that results in the highest sequence similarity. 
Non-conservative modi?cations of a particular polypep 
tide are those Which substitute any amino acid not character 
iZed as a conservative substitution. For example, any substi 
tution Which crosses the bounds of the six groups set forth 
above. These include substitutions of basic or acidic amino 
acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gln for 
Val, lle, Leu or Met), aromatic amino acid for basic or acidic 
amino acids (e.g., Phe, Tyr or Trp for Asp, Asn, Glu or Gln) or 
any other substitution not replacing an amino acid With a like 
amino acid. Basic amino acids include lysine (K), arginine 
(R), histidine (H); acidic amino acids include aspartic acid 
(D), glutamic acid (E); uncharged polar amino acids include 
glycine (G), asparagine (N), glutamine (Q), serine (S), threo 
nine (T), tyrosine (Y), cysteine (C); nonpolar amino acids 
include alanine (A), valine (V), leucine (L), isoleucine (I), 
proline (P), phenylalanine (F), methionine (M), tryptophan 
(W); beta-branched amino acids include threonine (T), valine 
(V), isoleucine (I); aromatic amino acids include tyrosine 
(Y), phenylalanine (F), tryptophan (W), histidine (H). 
A polynucleotide, polypeptide, or other component is “iso 
lated” When it is partially or completely separated from com 
ponents With Which it is normally associated (other proteins, 
nucleic acid molecules, cells, synthetic reagents, etc.). A 
nucleic acid molecule or polypeptide is “recombinant” When 
it is arti?cial or engineered, or derived from an arti?cial or 
engineered protein or nucleic acid molecule. For example, a 
polynucleotide that is inserted into a vector or any other 
heterologous location, e.g., in a genome of a recombinant 
organism, such that it is not associated With nucleotide 
sequences that normally ?ank the polynucleotide as it is 
found in nature is a recombinant polynucleotide. A protein 
expressed in vitro or in vivo from a recombinant polynucle 
otide is an example of a recombinant polypeptide. Likewise, 
a polynucleotide sequence that does not appear in nature, for 
example a variant of a naturally occurring gene, is recombi 
nant. For example, an “isolated” nucleic acid molecule is one 
Which is separated from other nucleic acid molecules Which 
are present in the natural source of the nucleic acid molecule. 
For example, With regards to genomic DNA, the term “iso 
lated” includes nucleic acid molecules Which are separated 
from the chromosome With Which the genomic DNA is natu 
rally associated. Typically, an “isolated” nucleic acid mol 
ecule is free of sequences Which naturally ?ank the nucleic 
acid molecule (i.e., sequences located at the 5' and 3' ends of 
the nucleic acid molecule) in the genomic DNA of the organ 
ism from Which the nucleic acid molecule is derived. For 
example, in various embodiments, the isolated nucleic acid 
molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 
kb, 0.5 kb or 0.1 kb of nucleotide sequences Which naturally 
?ank the nucleic acid molecule in genomic DNA of the cell 
from Which the nucleic acid molecule is derived. Moreover, 
an “isolated” nucleic acid molecule, such as a cDNA mol 
ecule, can be substantially free of other cellular material, or 
culture medium When produced by recombinant techniques, 
or substantially free of chemical precursors or other chemi 
cals When chemically synthesiZed. 
In some embodiments, a polypeptide provided herein 
includes amino acid residue substitutions that correspond to 
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positions in a particular sequence at least 80%, 85%, 90%, 
95%, 98% or 99% of the time. In other Words, the invention 
encompasses polypeptides that contain the recited amino acid 
substitutions at 80%, 85%, 90%, 95%, 98% or 99% of the 
recited positions in a given sequence. The skilled artisan Will 
recogniZe that not every substitution from a group of substi 
tutions is necessary to obtain a modi?ed polypeptide that is 
active on a triterpene substrate: 
“Sequence identity” herein means the extent to Which tWo 
nucleotide or amino acid sequences are invariant. “Sequence 
alignment” means the process of lining up tWo or more 
sequences to achieve maximal levels of identity (and, in the 
case of amino acid sequences, conservation) for the purpose 
of assessing the degree of similarity. Numerous methods for 
aligning sequences and assessing similarity/identity are 
knoWn in the art such as, for example, the Cluster Method, 
Wherein similarity is based on the MEGALIGN algorithm, as 
Well as BLASTN, BLASTP, and FASTA (Lipman and Pear 
son, (1985), Pearson and Lipman, (1988)). When using all of 
these programs, the preferred settings are those that results in 
the highest sequence similarity. For example, the “identity” or 
“percent identity” With respect to a particular pair of aligned 
amino acid sequences can refer to the percent amino acid 
sequence identity that is obtained by ClustalW analysis (ver 
sion W 1.8 available from European Bioinformatics Institute, 
Cambridge, UK), counting the number of identical matches 
in the alignment and dividing such number of identical 
matches by the greater of (i) the length of the aligned 
sequences, and (ii) 96, and using the folloWing default Clust 
alW parameters to achieve sloW/accurate pairWise align 
mentsiGap Open Penalty: 10; Gap Extension Penalty: 0.10; 
Protein Weight matrix: Gonnet series; DNA Weight matrix: 
IUB; Toggle SloW/Fast pairWise alignmentsISLOW or 
FULL Alignment. 
TWo sequences are “optimally aligned” When they are 
aligned for similarity scoring using a de?ned amino acid 
substitution matrix (e.g., BLOSUM62), gap existence pen 
alty and gap extension penalty so as to arrive at the highest 
score possible for that pair of sequences. Amino acid substi 
tution matrices and their use in quantifying the similarity 
betWeen tWo sequences are Well-knoWn in the art and 
described, e.g., in Dayhoff et al. (1978) “A model of evolu 
tionary change in proteins” in “Atlas of Protein Sequence and 
Structure,”Vol. 5, Suppl. 3 (ed. M. O. Dayhoff), pp. 345-352. 
Natl. Biomed. Res. Found, Washington, DC. and Henikoffet 
al. (1992)Pr0c. Naz’l. Acad. Sci. USA 89: 10915-10919 (each 
of Which is incorporated by reference). The BLOSUM62 
matrix is often used as a default scoring substitution matrix in 
sequence alignment protocols such as Gapped BLAST 2.0. 
The gap existence penalty is imposed for the introduction of 
a single amino acid gap in one of the aligned sequences, and 
the gap extension penalty is imposed for each additional 
empty amino acid position inserted into an already opened 
gap. The alignment is de?ned by the amino acids positions of 
each sequence at Which the alignment begins and ends, and 
optionally by the insertion of a gap or multiple gaps in one or 
both sequences so as to arrive at the highest possible score. 
While optimal alignment and scoring can be accomplished 
manually, the process is facilitated by the use of a computer 
implemented alignment algorithm, e.g., gapped BLAST 2.0, 
described in Altschul et al. (1997) Nucl. Acids Res. 25: 3389 
3402 (incorporated by reference herein), and made available 
to the public at the National Center for Biotechnology Infor 
mation (NCB1) Website (WWW.ncbi.nlm.nih.gov). Optimal 
alignments, including multiple alignments, can be prepared 
using, e.g., PSI-BLAST, available through the NCB1 Website 
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and described by Altschul et al. (1997) Nucl. Acids Res. 
2513389-3402 (incorporated by reference herein). 
With respect to an amino acid sequence that is optimally 
aligned With a reference sequence, an amino acid residue 
“corresponds to” the position in the reference sequence With 
Which the residue is paired in the alignment. The “position” is 
denoted by a number that sequentially identi?es each amino 
acid in the reference sequence based on its position relative to 
the N-terminus. For example, in SEQ ID N012, position 1 is 
M, position 2 is T, position 3 is M, etc. When a test sequence 
is optimally aligned With SEQ ID N012, a residue in the test 
sequence that aligns With the M at position 3 is said to “cor 
respond to position 3” of SEQ ID N012. Owing to deletions, 
insertion, truncations, fusions, etc., that must be taken into 
account When determining an optimal alignment, in general 
the amino acid residue number in a test sequence as deter 
mined by simply counting from the N-terminal Will not nec 
essarily be the same as the number of its corresponding posi 
tion in the reference sequence. For example, in a case Where 
there is a deletion in an aligned test sequence, there Will be no 
amino acid that corresponds to a position in the reference 
sequence at the site of deletion. Where there is an insertion in 
an aligned reference sequence, that insertion Will not corre 
spond to any amino acid position in the reference sequence. In 
the case of truncations or fusions there can be stretches of 
amino acids in either the reference or aligned sequence that do 
not correspond to any amino acid in the corresponding 
sequence. 
Also contemplated are fragments of the full length triter 
pene synthase polypeptides and polynucleotides, e.g., frag 
ments of polypeptides comprising the amino acid sequence 
set forth in SEQ ID NO: 2 and fragments of nucleic acid 
molecules comprising the sequence set forth in SEQ ID N01 
1. A “fragment” is a unique portion of a triterpene synthase 
polypeptide or the polynucleotide encoding triterpene syn 
thase Which is identical in sequence to, but shorter in length 
than, the parent sequence. A fragment may comprise up to the 
entire length of the de?ned sequence, minus one nucleotide/ 
amino acid residue. For example, a fragment may comprise 
from 5 to 1000 contiguous nucleotides or amino acid residues 
of a given nucleic acid molecule or polypeptide. A fragment 
used as a probe, primer, antigen, catalytic molecule, or for 
otherpurposes, maybe atleast 5, 10, 15, 16, 20, 25, 30, 40, 50, 
60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or 
amino acid residues in length. Fragments may be preferen 
tially selected from certain regions of a molecule. For 
example, a polypeptide fragment may comprise a certain 
length of contiguous amino acids selected from the ?rst 250 
or 500 amino acids (or ?rst 25% or 50%) of a polypeptide as 
shoWn in a certain de?ned sequence. Clearly these lengths are 
exemplary, and any length that is supported by the speci?ca 
tion, including the Sequence Listing, tables, and ?gures, may 
be encompassed by the present embodiments. 
Also contemplated in this invention are isolated polypep 
tides that are triterpene synthases, that comprise 5 peptide 
domains I, II, III, IV, andV. The peptide domains I, II, III, IV, 
and V of the triterpene synthase of this invention may com 
prise respectively, e.g., SEQ ID N01 3, SEQ ID N01 4, SEQ 
ID N01 5, SEQ ID N01 6, and SEQ ID N01 7 (See FIG. 6, the 
5 domains of B. braunii (BBS)). In an embodiment of the 
invention, domain I comprises an amino acid sequence that is 
at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% 
identical to the full-length of SEQ ID N01 3, domain II 
comprises an amino acid sequence that is at least 20%, 30%, 
40%, 50%, 60%, 70%, 80%, 90% or 95% identical the full 
length of SEQ ID N01 4, domain III may comprise an amino 
acid sequence that is at least 20%, 30%, 40%, 50%, 60%, 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
1 0 
70%, 80%, 90% or 95% identical to the full-length of SEQ ID 
N01 5, domain IV comprises an amino acid sequence that is 
at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% 
identical to the full-length of SEQ ID N01 6 and domain V 
comprises an amino acid sequence that is at least 20%, 305, 
40%, 50%, 60%, 70%, 80%, 90% or 95% identical the full 
length of SEQ ID N01 7. The 5 peptide domains may be 
present in the synthase in any order, preferably the order of the 
5 peptides in the polypeptide is, from its amino to carboxy 
terminal, I, II, III, IV, andV, and more preferably the I, II, III, 
IV andV domains comprise respectively SEQ ID N01 3, SEQ 
ID N01 4, SEQ ID N01 5, SEQ ID N016 and SEQ ID N017. 
In other embodiments, isolated nucleic acid molecules are 
provided. Described herein are nucleic acid molecules that 
encode a polypeptide having triterpene synthase activity, in 
particular a Bolryococcus braunii triterpene synthase. The 
nucleic acid molecules of this invention include e.g., nucleic 
acid molecules that encode the amino acid sequence set forth 
in SEQ ID N01 2, nucleic acid molecules that encode frag 
ments of SEQ ID N01 2, nucleic acidmolecules that comprise 
SEQ ID N011, and nucleic acid molecules that encode frag 
ments of SEQ ID N01 1. In one aspect, the invention provides 
a novel family of isolated or recombinant polynucleotides 
referred to herein as “triterpene synthase polynucleotides” or 
“triterpene synthase nucleic acid molecules.” Triterpene syn 
thase polynucleotide sequences are characterized by the abil 
ity to encode a triterpene synthase polypeptide. In general, the 
invention includes any nucleotide sequence that encodes any 
of the novel triterpene synthase polypeptides described 
herein. The terms “polynucleotide,” “nucleotide sequence,” 
and “nucleic acid molecule” are used to refer to a polymer of 
nucleotides (A, C, T, U, G, etc. or naturally occurring or 
arti?cial nucleotide analogues), e. g., DNA or RNA, or a rep 
resentation thereof, e. g., a character string, etc., depending on 
the relevant context. A given polynucleotide or complemen 
tary polynucleotide can be determined from any speci?ed 
nucleotide sequence. 
In an aspect, the triterpene synthase polynucleotides com 
prise recombinant or isolated forms of naturally occurring 
nucleic acid molecules isolated from an organism, e.g., an 
algae strain. Exemplary triterpene synthase polynucleotides 
include those that encode the polypeptide set forth in SEQ ID 
N012. In another aspect of the invention, triterpene synthase 
polynucleotides are produced by diversifying, e.g., mutating, 
a naturally occurring, isolated, or recombinant triterpene syn 
thase polynucleotide, e.g., the nucleic acid sequence set forth 
in SEQ ID N01 1. It is possible to generate diversi?ed triter 
pene synthase polynucleotides encoding triterpene synthase 
polypeptides With superior functional attributes, e. g., 
increased catalytic function, increased stability, or higher 
expression level, than a triterpene synthase encoded by the 
polynucleotide used as a substrate or parent in the diversi? 
cation process. 
The polynucleotides of the invention have a variety of uses 
in, for example recombinant production (i.e., expression) of 
the triterpene synthase polypeptides of the invention and as 
substrates for further diversity generation, e.g., recombina 
tion reactions or mutation reactions to produce neW and/or 
improved triterpene synthase homologues, and the like. 
It is important to note that certain speci?c, substantial and 
credible utilities of triterpene synthase polynucleotides do not 
require that the polynucleotide encode a polypeptide With 
substantial triterpene synthase activity or even variant triter 
pene synthase activity. For example, triterpene synthase poly 
nucleotides that do not encode active enZymes can be valu 
able sources of parental polynucleotides for use in 
diversi?cation procedures to arrive at triterpene synthase 
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polynucleotide variants, or non-triterpene synthase poly 
nucleotides, With desirable functional properties (e.g., high 
kcat or kcat/Km, loW Km, high stability towards heat or other 
environmental factors, high transcription or translation rates, 
resistance to proteolytic cleavage, etc.). 
Triterpene synthase polynucleotides, including nucleotide 
sequences that encode triterpene synthase polypeptides and 
variants thereof, fragments of triterpene synthase polypep 
tides, related fusion proteins, or functional equivalents 
thereof, are used in recombinant DNA molecules that direct 
the expression of the triterpene synthase polypeptides in 
appropriate host cells, such as plant cells. Due to the inherent 
degeneracy of the genetic code, other nucleic acid sequences 
Which encode substantially the same or a functionally equiva 
lent amino acid sequence can also be used to clone and 
express the triterpene synthase polynucleotides. The term 
“host cell”, as used herein, includes any cell type Which is 
susceptible to transformation With a nucleic acid construct. 
The term “transformation” means the introduction of a for 
eign (i.e., extrinsic or extracellular) gene, DNA or RNA 
sequence to a host cell, so that the host cell Will express the 
introduced gene or sequence to produce a desired substance, 
typically a protein or enzyme coded by the introduced gene or 
sequence. The introduced gene or sequence may include 
regulatory or control sequences, such as start, stop, promoter, 
signal, secretion, or other sequences used by the genetic 
machinery of the cell. A host cell that receives and expresses 
introduced DNA or RNA has been “transformed” and is a 
“transformant” or a “clone.” The DNA or RNA introduced to 
a host cell can come from any source, including cells of the 
same genus or species as the host cell, or cells of a different 
genus or species. 
As Will be understood by those of skill in the art, it can be 
advantageous to modify a coding sequence to enhance its 
expression in a particular host. The genetic code is redundant 
With 64 possible codons, but most organisms preferentially 
use a subset of these codons. The codons that are utilized most 
often in a species are called optimal codons, and those not 
utilized very often are classi?ed as rare or loW-usage codons 
(see, e.g., Zhang et al. (1991) Gene 105161-72; incorporated 
by reference herein). Codons can be substituted to re?ect the 
preferred codon usage of the host, a process sometimes called 
“codon optimization” or “controlling for species codon bias.” 
Optimized coding sequences containing codons preferred 
by a particular prokaryotic or eukaryotic host (see also, Mur 
ray et al. (1 989) Nucl. Acids Res. 171477-508; incorporated by 
reference herein) can be prepared, for example, to increase 
the rate of translation or to produce recombinant RNA tran 
scripts having desirable properties, such as a longer half-life, 
as compared With transcripts produced from a non-optimized 
sequence. Translation stop codons can also be modi?ed to 
re?ect host preference. For example, preferred stop codons 
for S. cerevisiae and mammals are UAA and UGA, respec 
tively. The preferred stop codon for monocotyledonous plants 
is UGA, Whereas insects and E. coli prefer to use UAA as the 
stop codon (Dalphin et al. (1996) Nucl. Acids Res. 24: 216 
218; incorporated by reference herein). Methodology for 
optimizing a nucleotide sequence for expression in a plant is 
provided, for example, in US. Pat. No. 6,015,891, and the 
references cited therein (incorporated herein by reference). 
“Silent variations” are one species of “conservative substi 
tutions.” One of skill Will recognize that each codon in a 
nucleic acid sequence (except AUG, Which is ordinarily the 
only codon for methionine) can be modi?ed by standard 
techniques to encode a functionally identical polypeptide. 
Accordingly, each silent variation of a nucleic acid sequence 
that encodes a polypeptide is implicit in any described 
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sequence. The invention provides each and every possible 
variation of nucleic acid sequence encoding a polypeptide of 
the invention that could be made by selecting combinations 
based on possible codon choices. These combinations are 
made in accordance With the standard triplet genetic code as 
applied to the nucleic acid sequence encoding a triterpene 
synthase homologue polypeptide of the invention. All such 
variations of every nucleic acid sequence herein are speci? 
cally provided and described by consideration of the 
sequence in combination With the genetic code. Any variant 
can be produced as noted herein. 
In general, the invention includes any polypeptide encoded 
by a modi?ed triterpene synthase polynucleotide derived by 
mutation, recursive sequence recombination, and/or diversi 
?cation of the polynucleotide sequences described herein. In 
some aspects of the invention, a triterpene synthase polypep 
tide is modi?ed by single or multiple amino acid substitu 
tions, a deletion, an insertion, or a combination of one or more 
of these types of modi?cations. Substitutions can be conser 
vative or non-conservative, can alter function or not, and can 
add neW function. Insertions and deletions can be substantial, 
such as the case of a truncation of a substantial fragment of the 
sequence, or in the fusion of additional sequence, either inter 
nally or at N or C terminal. 
An aspect of the invention pertains to isolated nucleic acid 
molecules that encode modi?ed triterpene synthase polypep 
tides or biologically active portions thereof. As used herein, 
the term “nucleic acid molecule” is intended to include DNA 
molecules (e.g., cDNA or genomic DNA) and RNA mol 
ecules (e.g., mRNA) and analogs of the DNA or RNA gener 
ated using nucleotide analogs. The nucleic acid molecule can 
be single-stranded or double-stranded, but preferably is 
double-stranded DNA. 
A nucleic acid molecule of the present invention, e.g., a 
nucleic acid molecule that encodes a polypeptide set forth in 
SEQ ID NO12, or having the nucleotide sequence of set forth 
in SEQ ID NO: 1, or a portion thereof, can be isolated using 
standard molecular biology techniques and the sequence 
information provided herein. 
A nucleic acid molecule of the invention can be ampli?ed 
using cDNA, mRNA or alternatively, genomic DNA, as a 
template and appropriate oligonucleotide primers according 
to standard PCR ampli?cation techniques. The nucleic acid 
molecule so ampli?ed can be cloned into an appropriate vec 
tor and characterized by DNA sequence analysis. Further 
more, oligonucleotides corresponding to nucleotide 
sequences can be prepared by standard synthetic techniques, 
e.g., using an automated DNA synthesizer. In some embodi 
ments, an isolated nucleic acid molecule of the invention 
comprises a nucleic acid molecule Which is a complement of 
a nucleotide sequence encoding a polypeptide set forth in 
SEQ ID NO12, or complement of the nucleotide sequence set 
forth in SEQ ID NO11. In still another embodiment, an iso 
lated nucleic acid molecule of the invention comprises a 
nucleotide sequence Which is at least about 50%, 52%, 55%, 
60%, 62%, 65%, 70%, 75%, 78%, 80%, 85%, 88%, 90%, 
95%, 97%, 98% or more identical to the nucleotide sequence 
encoding a polypeptide set forth in SEQ ID NO12, or the 
nucleotide sequence set forth in SEQ ID NO: 1, or a portion of 
any of these nucleotide sequences. 
In addition to the nucleotide sequences encoding a 
polypeptide set forth in SEQ ID NO12, or the nucleotide 
sequence set forth in SEQ ID NO: 1, it Will be appreciated by 
those skilled in the art that DNA sequence polymorphisms 
that lead to changes in the amino acid sequences of the pro 
teins may exist Within a population. Such genetic polymor 
phisms may exist among individuals Within a population due 
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to natural allelic variation. Such natural allelic variations 
include both functional and non-functional proteins and can 
typically result in 1-5% variance in the nucleotide sequence 
of a gene. Any and all such nucleotide variations and resulting 
amino acid polymorphisms in genes that are the result of 
natural allelic variation and that do not alter the functional 
activity of a protein are intended to be Within the scope of the 
invention. 
Accordingly, in another embodiment, an isolated nucleic 
acid molecule of the invention hybridizes under stringent 
conditions to a nucleic acid molecule comprising the nucle 
otide sequence encoding a polypeptide set forth in SEQ ID 
N012, or the nucleotide sequence set forth in SEQ ID N011. 
In other embodiments, the nucleic acidmolecule is at least 30, 
50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, or 600 
nucleotides in length. Nucleic acid molecules are “hybridiz 
able” to each other When at least one strand of one polynucle 
otide can anneal to another polynucleotide under de?ned 
stringency conditions. Stringency of hybridization is deter 
mined, e.g., by (a) the temperature at Which hybridization 
and/or Washing is performed, and (b) the ionic strength and 
polarity (e.g., formamide) of the hybridization and Washing 
solutions, as Well as other parameters. Hybridization requires 
that the tWo polynucleotides contain substantially comple 
mentary sequences; depending on the stringency of hybrid 
ization, hoWever, mismatches may be tolerated. Typically, 
hybridization of tWo sequences at high stringency (such as, 
for example, in an aqueous solution of 0.5><SSC at 65° C.) 
requires that the sequences exhibit some high degree of 
complementarity over their entire sequence. Conditions of 
intermediate stringency (such as, for example, an aqueous 
solution of 2><SSC at 650 C.) and loW stringency (such as, for 
example, an aqueous solution of 2><SSC at 55° C.), require 
correspondingly less overall complementarity betWeen the 
hybridizing sequences (1><SSC is 0.15 M NaCl, 0.015 M Na 
citrate). 
Nucleic acid molecules that hybridize include those Which 
anneal under suitable stringency conditions and Which 
encode polypeptides or enzymes having the same function, 
such as the ability to catalyze the reductive condensation of 2 
famexyl diphosphate (FPP) substrate molecules yielding bot 
ryococcene, a 30-carbon branched-chain hydrocarbon, of the 
invention. Further, the term “hybridizes under stringent con 
ditions” is intended to describe conditions for hybridization 
and Washing under Which nucleotide sequences at least 30%, 
40%, 50%, or 60% homologous to each other typically 
remain hybridized to each other. Preferably, the conditions 
are such that sequences at least about 70%, more preferably at 
least about 80%, even more preferably at least about 85% or 
90% homologous to each other typically remain hybridized to 
each other. In some cases, an isolated nucleic acid molecule of 
the invention that hybridizes under stringent conditions to a 
nucleic acid sequence encoding a polypeptide set forth in any 
of SEQ ID N012, or the nucleotide sequence set forth in SEQ 
ID N011, corresponds to a naturally-occurring nucleic acid 
molecule. As used herein, a “naturally-occurring” nucleic 
acid molecule refers to an RNA or DNA molecule having a 
nucleotide sequence that occurs in nature (e.g., encodes a 
natural protein). Preferably the nucleic acid molecule that 
hybridizes, hybridizes to at least 30%, 40%, 50%, 60%, 70%, 
80%, 85% or 90% of the length of a nucleic acid molecule 
consisting of SEQ ID N011 under stringent conditions. More 
preferably the nucleic acid molecule that hybridizes, hybrid 
izes to at least about 80%, even more preferably at least about 
85% or 90% of the length of a nucleic acid molecule consist 
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ing of SEQ ID N01 1. Preferably the nucleic acid molecule 
that hybridizes encodes a polypeptide having triterpene syn 
thase activity. 
The skilled artisan Will appreciate that changes can be 
introduced by mutation into the nucleotide sequences of any 
nucleic acid sequence encoding a polypeptide set forth in 
SEQ ID N012, or having the nucleotide sequence set forth in 
SEQ ID N011, thereby leading to changes in the amino acid 
sequence of the encoded proteins. In some cases the alteration 
Will lead to altered function of the polypeptide. In other cases 
the change Will not alter the functional ability of the encoded 
polypeptide. In general, substitutions that do not alter the 
function of a polypeptide include nucleotide substitutions 
leading to amino acid substitutions at “non-essential” amino 
acid residues. Generally these substitutions can be made in, 
for example, the sequence encoding a polypeptide set forth in 
SEQ ID N012, or having the nucleotide sequence set forth in 
SEQ ID N011, Without altering the ability of the enzyme to 
catalyze the reductive condensation of FPP substrate. A “non 
essential” amino acid residue is a residue that can be altered 
from the parent sequence Without altering the biological 
activity of the resulting polypeptide, e.g., catalyzing the 
reductive condensation of 2 FPP to yield botryococcene. 
Also contemplated are those situations Where it is desirable 
to alter the activity of a parent polypeptide such that the 
polypeptide has neW or increased activity on a particular 
substrate. It is understood that these amino acid substitutions 
Will generally not constitute “conservative” substitutions. 
Instead, these substitutions constitute non-conservative sub 
stitutions introduced in to a sequence in order to obtain a neW 
or improved activity. 
It is also understood that an isolated nucleic acid molecule 
encoding a polypeptide homologous to the polypeptide of 
SEQ ID N012 can be created by introducing one or more 
nucleotide substitutions, additions or deletions into the nucle 
otide sequence encoding the particular polypeptide, such that 
one or more amino acid substitutions, additions or deletions 
are introduced into the encoded protein. Mutations can be 
introduced into the nucleic acid sequence by standard tech 
niques, such as site-directed mutagenesis and PCR-mediated 
mutagenesis. In contrast to those positions Where it may be 
desirable to make a non-conservative amino acid substitu 
tions (see above), in some positions it is preferable to make 
conservative amino acid substitutions. 
Mutational methods of generating diversity include, for 
example, site-directed mutagenesis (Ling et al. (1997) Anal 
Brioche. 254(2)1 157-178; Dale et al. (1996) Methods Mol. 
Biol. 571369-374; Smith (1985)Ann. Rev. Genet. 191423-462; 
Botstein & Shortle (1985) Science 22911193-1201; Carter 
(1986) Biochem. J. 23711-7; and Kunkel (1987) “The e?i 
ciency of oligonucleotide directed mutagenesis” in Nucleic 
Acids & Molecular Biology (Eckstein, F. and Lilley, D. M. J . 
eds., Springer Verlag, Berlin)); mutagenesis using uracil con 
taining templates (Kunkel (1985) Proc. Natl. Acad. Sci. USA 
821488-492; Kunkel et al. (1987) Methods in Enzymol. 154, 
367-382; and Bass et al. (1988) Science 2421240-245); oligo 
nucleotide-directed mutagenesis (Methods in Enzymol. 1001 
468-500 (1983); Methods in Enzymol. 1541 329-350 (1987); 
Zoller & Smith (1982) Nucleic Acids Res. 1016487-6500; 
Zoller & Smith (1983) Methods in Enzymol. 1001468-500; 
and Zoller & Smith (1987) Methods in Enzymol. 1541329 
350); phosphorothioate-modi?ed DNA mutagenesis (Taylor 
et al. (1985) Nucl. Acids Res. 131 8749-8764; Taylor et al. 
(1985) Nucl. Acids Res. 131 8765-8787; Nakamaye & Eck 
stein (1986) Nucl. Acids Res. 141 9679-9698; Sayers et al. 
(1988) Nucl. Acids Res. 161791-802; and Sayers et al. (1988) 
Nucl. Acids Res. 161 803-814); mutagenesis using gapped 
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duplex DNA (Kramer et al. (1984)Nucl. Acids Res. 12: 9441 - 
9456; Kramer & FritZ (1987) Methods in Enzymol. 154:350 
367; Kramer et al. (1988)Nucl. Acids Res. 16: 7207; and Fritz 
et al. (1988) Nucl. Acids Res. 16: 6987-6999) (each ofWhich 
is incorporated by reference). 
Additional suitable methods include point mismatch repair 
(Kramer et al. (1984) Cell 38:879-887), mutagenesis using 
repair-de?cient host strains (Carter et al. (1985) Nucl. Acids 
Res. 13: 4431-4443; and Carter (1987) Methods in Enzymol. 
154: 382-403), deletion mutagenesis (EghtedarZadeh & 
Henikoff (1986) Nucl. Acids Res. 14: 5115), restriction-se 
lection and restriction-puri?cation (Wells et al. (1986) Phil. 
Trans. R. Soc. Lond. A 317: 415-423), mutagenesis by total 
gene synthesis (Nambiar et al. (1984) Science 223: 1299 
1301; Sakamar and Khorana (1988) Nucl. Acids Res. 14: 
6361 -6372; Wells et al. (1985) Gene 34:315-323; and Grund 
strom et al. (1985) Nucl. Acids Res. 13: 3305-3316); double 
strand break repair (Mandecki (1 986) ; Arnold (1993) Current 
Opinion in Biotechnology 4:450-455; and Proc. Natl. Acad. 
Sci. USA, 83:7177-7181) (each of Which is incorporated by 
reference). Additional details on many of the above methods 
can be found in Methods in Enzymology (1987) Volume 154, 
Which also describes useful controls for trouble-shooting 
problems With various mutagenesis methods. 
Additional details regarding various diversity generating 
methods can be found in the folloWing U.S. patents, PCT 
publications, and EPO publications: U.S. Pat. No. 5,605,793 
to Stemmer (Feb. 25, 1997); Us. Pat. No. 5,81 1,238 to Stem 
meret al. (Sep. 22, 1998); Us. Pat. No. 5,830,721 to Stemmer 
et al. (Nov. 3, 1998); Us. Pat. No. 5,834,252 to Stemmer, et 
al. (Nov. 10, 1998); Us. Pat. No. 5,837,458 to Minshull, et al. 
(Nov. 17, 1998); WO 95/22625, Stemmer and Crameri; WO 
96/33207 by Stemmer and LipschutZ; WO 97/20078 by 
Stemmer and Crameri; W0 97/ 35966 by Minshull and Stem 
mer; WO 99/41402 by Punnonen et al.; WO 99/41383 by 
Punnonen et al.; WO 99/41369 by Punnonen et al.; WO 
99/41368 by Punnonen et al.; EP 752008 by Stemmer and 
Crameri; EP 0932670 by Stemmer; WO 99/23107 by Stem 
mer et al.; WO 99/21979 by Apt et al.; WO 98/31837 by del 
Cardayre et al.; WO 98/27230 by Patten and Stemmer; WO 
98/13487 by Stemmer et al.; WO 00/00632; WO 00/09679; 
WO 98/42832 by Arnold et al.; WO 99/29902 byArnold et al.; 
WO 98/41653 by Vind; WO 98/41622 by Borchert et al.; WO 
98/42727 by Pati and Zarling; WO 00/18906 by Patten et al.; 
WO 00/04190 by del Cardayre et al.; WO 00/42561 by 
Crameri et al.; WO 00/42559 by Selifonov and Stemmer; WO 
00/42560 by Selifonov et al.; WO 01/23401 by Welch et al.; 
and W0 01/ 64864 by Affholter (each of Which is incorpo 
rated by reference). The QUICKCHANGETM protocol mar 
keted by Stratagene of San Diego, Calif. is one speci?c 
method known to those skilled in the art for introducing 
site-directed mutations. This method relies on the use of oligo 
or DNA primer pairs, harboring speci?c DNA sequence 
changes to be introduced, annealed to the target DNA or gene 
to be modi?ed. Copies of modi?ed DNA/ gene are ampli?ed 
by standard PCR methodology. Con?rmation of alteration of 
the target DNA sequence is veri?able by automated DNA 
sequencing. 
Also provided are recombinant constructs comprising one 
or more of the nucleic acid sequences as broadly described 
above. The constructs comprise a vector, such as, a plasmid, 
a cosmid, a phage, a virus, a bacterial arti?cial chromosome 
(BAC), a yeast arti?cial chromosome (YAC), or the like, into 
Which a nucleic acid sequence of the invention has been 
inserted, in a forWard or reverse orientation. In a preferred 
aspect of this embodiment, the construct further comprises 
regulatory sequences including, for example, a promoter 
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operably linked to the sequence. Large numbers of suitable 
vectors and promoters are knoWn to those of skill in the art, 
and are commercially available. 
Accordingly, in other embodiments, vectors that include a 
nucleic acid molecule of the invention are provided. 
In other embodiments, host cells transfected With a nucleic 
acid molecule of the invention, or a vector that includes a 
nucleic acid molecule of the invention, are provided. Host 
cells include eucaryotic cells such as yeast cells, e.g., yeast 
cells having a ERGl knockout, e.g., the yeast strain TN7 
described in co-pending application Ser. No. 12/489,038 
incorporated herein in its entirety, insect cells, animal cells, or 
plant cells (e. g., algal cells or terrestrial plant cells). Host cells 
also include procaryotic cells such as bacterial cells. 
The terms “vector”, “vector construct” and “expression 
vector” mean the vehicle by Which a DNA or RNA sequence 
(eg a foreign gene) can be introduced into a host cell, so as 
to transform the host and promote expression (e.g. transcrip 
tion and translation) of the introduced sequence. Vectors typi 
cally comprise the DNA of a transmissible agent, into Which 
foreign DNA encoding a protein is inserted by restriction 
enZyme technology. A common type of vector is a “plasmid”, 
Which generally is a self-contained molecule of double 
stranded DNA that can readily accept additional (foreign) 
DNA and Which can readily introduced into a suitable host 
cell. A large number of vectors, including plasmid and viral 
vectors, have been described for replication and/ or expression 
in a variety of eukaryotic and prokaryotic hosts. Non-limiting 
examples include pKK plasmids (Clonetech), pUC plasmids, 
pET plasmids (Novagen, Inc., Madison, Wis.), pRSET or 
pREP plasmids (lnvitrogen, San Diego, Calif), pMAL plas 
mids (N eW England Biolabs, Beverly, Mass.), and Ti plasmid 
vectors, and many appropriate host cells, using methods dis 
closed or cited herein or otherWise knoWn to those skilled in 
the relevant art. Vectors can also be selected such that expres 
sion of the introduced sequence is targeted to a chloroplast in 
a plant cell. Recombinant cloning vectors Will often include 
one or more replication systems for cloning or expression, 
one or more markers for selection in the host, e. g., antibiotic 
resistance, and one or more expression cassettes. 
The terms “express” and “expression” mean alloWing or 
causing the information in a gene or DNA sequence to 
become manifest, for example producing a protein by acti 
vating the cellular functions involved in transcription and 
translation of a corresponding gene or DNA sequence. A 
DNA sequence is expressed in or by a cell to form an “expres 
sion product” such as a protein. The expression product itself, 
eg the resulting protein, may also be said to be “expressed” 
by the cell. A polynucleotide or polypeptide is expressed 
recombinantly, for example, When it is expressed or produced 
in a foreign host cell under the control of a foreign or native 
promoter, or in a native host cell under the control of a foreign 
promoter. 
Polynucleotides provided herein can be incorporated into 
any one of a variety of expression vectors suitable for express 
ing a polypeptide. Suitable vectors include chromosomal, 
nonchromosomal and synthetic DNA sequences, e. g., deriva 
tives of SV40; bacterial plasmids; phage DNA; baculovirus; 
yeast plasmids; vectors derived from combinations of plas 
mids and phage DNA, viral DNA such as vaccinia, adenovi 
rus, foWl pox virus, pseudorabies, adenovirus, adeno-associ 
ated viruses, retroviruses; Ti plasmids for the incorporation 
and expression of DNA in plant cells, and many others. Any 
vector that transduces genetic material into a cell, and, if 
replication is desired, Which is replicable and viable in the 
relevant host can be used. 













